Developing a unique mRNA platform
Combined Therapeutics is an emerging mRNA medicines company developing a unique modified mRNA platform to protect vulnerable populations from global infectious diseases as well as to cure cancer.
Fueled by our proprietary technologies, which target protein expression to specific tissues while reducing off target effects, combined with an experienced team in delivery and mRNA-based therapeutics, we are committed to harnessing the body’s machinery to protect and improve patients’ lives.
About Us
Combined Therapeutics has developed a unique platform built around Multi Organ Protective (MOP) miRNA sequences combined to therapeutic mRNAs, that allow to target and focus therapeutic protein expression in specific tissues, spare healthy tissues and reduce off target effects.
Together with our partners, we are committed to using our platform to protect vulnerable populations from global infectious disease threats as well as to cure cancer.

Board of Directors





Operational Team

Romain Micol MD, MPH, PhD, MBA, LLM
President and CEO (cofounder), Leadership

Thomas VanCott, PhD
CSO

Valérie Duval, PhD
Associate Director, Biology

Lauren Speciner, PhD
Principal Scientist, Formulation & Process Development

Kim Foster, MLS(ASCP)CM
Senior Research Associate, Biology

Asad Khanmohammed
Senior Research Associate, Formulation & Process Development

Walter James
Lab Manager

Pierre Vochel
Senior Manager Strategy & Finance, Finance & Strategy

Devenand Crease, PhD
Patent Attorney

Ronald E. Kaunfer, BSc
Accounting Director
Advisors / Consultants

Sarah Cooleybeck, J.D.
Corporate Attorney

Robert Langer, ScD
Cofounder – Oncology / Virotherapy

Dan Anderson, PhD
Cofounder – Oncology / Virotherapy

David Neafus, MBA
Financial Advisor
EXISTING Science LANDSCAPE
What are mRNA therapies
- Utilizes existing cell machinery to make therapeutic proteins that can treat disease
- Can be modified to produce therapeutic proteins only in the target cells, such as tumoral cells, and spare healthy tissue
- Nucleic acids therapies are a very versatile platform as they can code for any protein of interest and are transient; broken down quickly after their job is done
Our mRNA platform: Combined Therapeutics’ Drug and Modulation Platform (DMPCTx):
- A new generation of modified mRNA delivered in a lipid nanoparticle capable of targeted protein expression in specific tissues
- 3 routes of Administration: Intravenous, Intra-tumoral, Intramuscular
- 2 medical applications: Vaccines & Oncology
- Multi-Organ Protection (MOP): Treatment side effects occur when healthy cells are affected alongside diseased cells. MOP is key to delivering and focusing treatment to diseased cells only, thus preventing off target effects
Infectious disease – Prophylactic vaccine
- The success of mRNA vaccines in the global fight against COVID19 highlights the potential of this new class of medicines. RNA vaccines can be developed more rapidly than traditional vaccines to tackle infectious disease outbreaks and can be leveraged to direct the immune system more effectively against infectious diseases
- We can use our unique approach to develop next generation vaccines. Our infectious disease vaccine candidates contain modified mRNA-encoding antigens to specifically activate an immune response, allowing the body to fend off future infections. At Combined Therapeutics we can deliver multiple mRNAs that encode for both an antigen and an immunomodulator. This dual approach boosts the immune response against the infection, leading to better disease protection
Oncology
- Immunotherapy is a promising approach that bolsters the patient immune system to fight his own cancer. However, it can generate severe adverse effects and exhibits a low response rate, particularly in solid cancers with an immunosuppressive microenvironment
- DMPCTx revolutionizes the treatment of solid tumors:
- Protect: Following a systemic administration of mRNA-based immunotherapy, DMPCTx safely produces therapeutic proteins in tumor cells only, fully sparing healthy tissues, reducing systemic toxicities and preserving safety
- Sensitize & Boost: DMPCTx platform can be harnessed as a companion boost to sensitize all tumors to any immunotherapeutic regimen, such as virotherapy, CAR T-cell therapy, and immune checkpoint inhibitors, and thus significantly enhance their efficacies
Use our solution to enhance your immunotherapy or Vaccine applications
News
2/15/23
Combined Therapeutics doses first animals in pivotal NHP study to show improved biodistribution and safety profile of their vaccine while maintaining efficacy.
1/28/23
Robert Ruffolo, Ph.D. and Kevin F. McLaughlin join Combined Therapeutics’ board of directors.
1/12/23
Combined Therapeutics presents at JP Morgan, San Francisco CA.
1/11/23
Combined Therapeutics presents at the Biotech Showcase, San Francisco, CA.
11/14/22
Combined Therapeutics presents at Jeffries, London, UK.
11/2/22
Combined Therapeutics demonstrates MOP technology mRNA vaccine as effective as conventional mRNA vaccines in Hamster efficacy study.
10/11/22
Boston Children’s Hospital presents results from their collaboration with Combined Therapeutics at the Vaccine Summit in Washington, DC.
10/3/22
Thomas VanCott joins Combined Therapeutics as CSO.
8/1/22
CTx headquarters move into a new facility in SmartLabs, Boston MA.
7/11/22
Walter James joins Combined Therapeutics as Lab Manager.
4/29/22
Paul Wotton, Ph.D. joins Combined Therapeutics’ board of directors.
5/1/22
CTx has won the Sanofi Golden Ticket in France – 12-month free access to the new, state of the art Biolabs space in Hotel Dieu, Paris.
4/1/22
CTx received €400k of grant support from the Banque Publique d’Investissement (BPI) in France.
3/14/22 – 3/16/22
Combined Therapeutics is invited to attend Pierre Fabre Virtual Biopharma Partnering in March 2022 to showcase the company and our innovative therapeutics.
10/4/21
Asad Khanmohammed joins Combined Therapeutics as Senior Research Associate.
1/25/21
Kim Foster joins Combined Therapeutics as Research Associate.